CRS 2017: Applying CVD/Lipids Guidelines in Your Practice

October 21, 2017 at 8am

Lower levels of LDL cholesterol, as well as the duration of low LDL, are important for the prevention and management of atherosclerotic cardiovascular disease (ASCVD), according to James Underberg, MS, MD, FACPM, FACP, FNLA, who presented “Applying CVD/Lipids Guidelines in Your Practice” earlier this morning.

Firstly, Underberg discussed the support for LDL causality in ASCVD, and the role that hepatic LDL receptors play in cholesterol homeostasis.

He went on to review data from studies examining the effects of LDL cholesterol-lowering therapies on rates of CHD, MI, secondary cardiovascular events, and major vascular events.

Next, he discussed current guidelines on the management of lipid levels and cardiovascular disease, specifically the 2013 ACCAHA Guideline for the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, the 2016 ESC/EAS Guidelines on the Management of Dyslipidemia, the 2016 ACC Expert Consensus Decision Pathway on Non-statin Therapies, the 2017 AACE Guidelines, and the 2017 NLA Expert Panel PCSK9 Inhibitor Recommendations.

Lastly, he examined the benefits of shared decision making, barriers to medication adherence, interventions to improve adherence, and how to determine when to add non-statin therapy.

—Michael Potts

Reference:

Underberg J. Applying CVD/lipids guidelines in your practice [presented at Cardiometabolic Risk Summit 2017]. Dallas, Texas. October 21, 2017.